Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Ai Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 570.00 69,276 08:00:16
Bid Price Offer Price High Price Low Price Open Price
560.00 580.00 570.00 570.00 570.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -0.42 -1.00 339
Last Trade Time Trade Type Trade Size Trade Price Currency
16:46:34 O 12,500 570.00 GBX

Renalytix Ai (RENX) Latest News

More Renalytix Ai News
Renalytix Ai Takeover Rumours

Renalytix Ai (RENX) Discussions and Chat

Renalytix Ai (RENX) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Renalytix Ai trades in real-time

Renalytix Ai (RENX) Top Chat Posts

Renalytix Ai Daily Update: Renalytix Ai Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENX. The last closing price for Renalytix Ai was 570p.
Renalytix Ai Plc has a 4 week average price of 465p and a 12 week average price of 232p.
The 1 year high share price is 575p while the 1 year low share price is currently 173.50p.
There are currently 59,416,134 shares in issue and the average daily traded volume is 203,440 shares. The market capitalisation of Renalytix Ai Plc is £338,671,963.80.
74tom: Re. Distribution of shares in Verici, it seems logical to grant shares in the new entity on a 1-1 basis. The book value of Verici is $2m, so they’ve minimised the ex dividend in specie impact on the RENX share price (it’ll be about 2.7p), IMO better to do it this way than the way EKF split off RENX, which resulted in a 30% ex div in specie markdown. My opinion is that they’ll look to raise around £20m when they IPO, and the pre cash valuation will likely be similar to the RENX IPO (£45m). They simply wouldn’t bother with the spin off process to list for much less than this. However, even a much lower pre IPO valuation of £20-25m would still result in a very nice paper profit vs the current book valuation... So based on the above assumptions, I’m happy with the 1 year lock in - it’s worth it to be get in at the very bottom. What are your thoughts?
74tom: The exciting thing about RENX is the combination of huge addressable target market, the presence of a significant and growing IP moat & the macro tailwinds driving market appetite for health-tech companies (especially those listed in the US). For these reasons alone the escalator can go an awful lot higher over the coming years. Stifel have forecast revenues of $390m in 5 years time. Comparators such as Guardant Health reported $67m revenue last quarter & are valued at over $8b. So evidently IF RENX can achieve their growth ambitions then the share price will take care of itself. @Nimbo I note Livongo smashed their Q2 target by around 20% ($86m revenue), the full year forecast was $300m (likely to be upgraded by a decent amount!), and they’re now valued at $9b so 30x revenue. The critical next step for RENX is recording first revenues via Mount Sinai, hopefully in the very near future...
74tom: Yes Nimbo1, I've been watching Puretech and think it's a very interesting (if complicated) business, certainly trading well below where it should be based on fundamentals! The only thing that puts me off at present is the circa 30% holding that Invesco has, as this is a major overhang and only obvious reason for the stagnant share price... But I'll certainly keep an eye on it :)
74tom: Agree Nimbo, timing the Nasdaq IPO with their first revenues was clearly the plan, and that will whet the appetite of many US investors I’d imagine, especially those aware of the macro factors. They’ve created a perfect storm as far as share price appreciation is concerned; - Existing holders have the FractalDX dividend in specie to look forward to, why would you sell when you’ll get a substantial number of free shares? - Nasdaq IPO - another exciting near term event, as we have seen with GAN this can result in a large value uplift in cases where a quality company has been relatively under the radar due to AIM liquidity. - Covid-19 involvement via Kantaro JV, this also has significant potential given the Antibody test has already received FDA EUA & has the second most accurate sensitivity / specificity of any test I’ve seen. What’s more the worldwide distribution via Bio-Techne is nailed down, so a July launch is very much on track. Expect to hear confirmation of this in the next week. Then we have the seamless underlying progress of KidneyIntelX™ described so well by Wan. Quite simply, if you sold here where else can you replicate this unique set of circumstances?
74tom: Yep, it's all to do with a restriction on US citizens buying shares which was in fact lifted on 5th May : httpS:// Barclays had a block on buying it until a couple of week ago, no such issues with HL. Try a different broker if you can, as clearly II haven't been bothered to lift the restriction yet...
nimbo1: The way I read this situation is Renx could be a good buy at this level assuming its product becomes successful in a relatively niche way. I.e. it does a few 1000 tests per month for people who want the extra insight - that could support todays share price. revenue c.£50 mil a year with margins at c.40%. i.e. c£15 mil PAT and PE of 30. The upside is it becomes ingrained as part of the US healthcare system as the standard practice for kidney which case you'll have a 10x +. Price needs to consolidate for a while imo.
wan: I note today's RNS Non-Regulatory, that a very key/influential individual has been recruited. hTTps://
wan: My interpretation of the need and use of Placing, which was "significantly oversubscribed with strong demand received from existing and new shareholders", was to accelerate matters, this has now been confirmed in last nights announcement - James McCullough, CEO of RenalytixAI, commented: "We are pleased to have achieved an oversubscribed placing supported by a broad range of investors, and thank them for their support. The Company will now be better resourced to support the acceleration of its commercial plans, having made rapid progress against its objectives as set out at the time of its IPO in November 2018." hTTps://
pugugly: The Company is pleased to confirm that relevant EKF shareholders on the register as at close of business on 23 October 2018 ("Relevant EKF Shareholders") will receive one RENX Share for every 21.825 EKF ordinary shares held. Entitlements will be rounded down to the nearest whole number of RENX Shares and fractional entitlements will be aggregated and sold in the open market with the net proceeds donated to charity, in line with the Company's articles.
the stigologist: The recent listings of Sensyne (SENS) (formerly known as Drayson Health) and Renalytix (RENX) have focused attention of UK investors on the new AI MedTech sector. Companies such as this in the AI/Machine Learning MedTech space "use anonymised data from the NHS to diagnose patterns in cancer and other diseases ...then pass on findings to drug companies so they can develop treatments faster and more cost-effectively than in the past." The rich valuations enjoyed by SENS and RENX have caused investors to look for other companies in the sector which may be 'hidden gems'. One such is Physiomics (PYC). Whilst Sensyne and Renalytix are valued at £240m and £70m despite have zero in revenues Physiomics is valued at only £3m AND has revenues of c. £0.5m However when considering how to value Physiomics it's important to realise there are two major strands to it's business. One strand is its 'legacy' Modelling and Simulation business which last year signed a E0.5m deal with Merck KgGA. This part of the business is analagous to the likes of Simulations Plus a $400m Mkt Cap Nasdaq listed comparitor with c.$20m in revenues. Thus one could apply a 'rating' of 10-20x revenues to value Physiomics business in this area. (£0.4m x 10-20x = £4.0-8.0m) The new strand to Physiomics business is it's AI/Personalised Medicine business. In this part of the business Physiomics has won research grant funding from the UK Government's InnovateUK to progress several studies on specific cancers in association with Oxford University academics and Oxford NHS. e.g. Oesophagal Cancer study hTtps:// Prostate Cancer study hTtps:// This part of Physiomics business is similar to and should be valued with reference to its newly listed comparitors Renalytix (RENX) and Sensyne (SENS). Those valuations would suggest a very wide potential range from £70m to £240m. Putting together the 'sum of the parts' we can conclude that a case can be made for valuing Physiomics currently as 'worth' somewhere within a range of £74-248m. In terms of share price with 72m shares in issue this would imply a potential valuation range of c.100-350p Clearly at a mere 5p the market has a lot of catching up to do in valuing Physiomics correctly.
Renalytix Ai share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Renalytix ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200712 07:09:00